May 9th, 2022
IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant
IPA subsidiary BioStrand receives grant to expand LENSai platform by linking HYFTs™ with 3D protein structure and function Diepenbeek, (Belgium), May 9, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is...